Search for a report

Reports

  • You are here:
  • Home
  • Downloads
  • GLOBAL ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026

GLOBAL ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026

The Global Antifungal agents market is anticipated to grow at a CAGR of 3.72% between 2018 and 2026. The antifungal agents are fungistatic in nature and are used to prevent and treat mycoses such as candidiasis, ringworm, etc. These are essentially the drugs which help in detecting and eliminating fungal pathogens from the foreign body with less toxic side effects to the body. The Antifungal agents market is primarily driven by the following factors:

GLOBAL ANTIFUNGAL AGENTS MARKET (DRUGS, THERAPIES & APPLICATIONS)  FORECAST 2018-2026

Global Antifungal Agents Market (Drugs, Therapies, & Applications) Market by Drug Types (Echinocandins, Azoles, Polyenes, Allylamines & Others) by Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others) by Applications (Topical Antifungal Drugs, Oral Drugs) by Geography

Request free sample

The Global Antifungal agents market is anticipated to grow at a CAGR of 3.72% between 2018 and 2026. The antifungal agents are fungistatic in nature and are used to prevent and treat mycoses such as candidiasis, ringworm, etc. These are essentially the drugs which help in detecting and eliminating fungal pathogens from the foreign body with less toxic side effects to the body. The Antifungal agents market is primarily driven by the following factors:

  • Poor hygiene habits
  • Development of drug resistance
  • Healthcare policies and programs by government

Antifungal Agents Market | Inkwood Research

To know more about this report, request a free sample copy.

The important driver increasing growth in the global antifungal agents market is the development of drug resistance. The growing concern amongst the population regarding health issue has positively influenced the growth in the medical sector. The infections like yeasts and pathogenic fungi can invade and overtake the human body. Hence, there is an increasing demand for antifungal drugs in the market.

The applications of antifungal agents market can be found extensively for various purposes. Topical drugs are those medications which are directly applied to the skin or the affected portion of the body. These come in wide forms like pastes, ointments, powder, and others. Most of the topical drugs have systematic effects because they are first absorbed by the skin and are then circulated. Oral antifungal agents include fluconazole, terbinafine, itraconazole, and ketoconazole. These oral antifungal agents are reserved for serious infection for which topical antifungal agents are ineffective or inappropriate. Most of the oral Antifungal agents are the medicines which are available only through prescription and are available in dosage forms such as capsules, suspensions, and tablets.

Alternate treatment options and regulatory atmosphere are the major factors hindering the growth of the antifungal agents market. There are various types of fungal infections for which patients take home remedies or the herbal treatments. This is restricting the growth of the antifungal agents market. Such alternative treatments are the types of the conventional drugs which are the major restricting factors of the market. At present, a large portion of the antifungal medications are outside value control, and there is a wide mystifying distinction between brands in terms of their retail costs.

The global antifungal agents market segments include drug types, therapeutic indications, types, and applications.

Drug Types are segmented into:

  • Systemic azoles
  • Topical azoles
  • Systemic polyenes
  • Topical polyenes
  • Systemic echinocandins
  • Systemic antimetabolics
  • Other systemic
  • Other topical
  • Other drugs types

Therapeutic Indications are segmented into:

  • Aspergillosis market
  • Dermatophytosis market
  • Candidiasis market
  • Others market

Types are segmented into:

  • Prescription
  • Over the counter (OTC)

Applications are segmented into:

  • Topical antifungal agents market
  • Oral drugs market

This report covers the present market conditions and the growth prospects of the global antifungal agents market for 2018-2026 and considered the revenue generated through the sales of antifungal agents for drug types, therapeutic indications, and applications in order to calculate the market size by considering 2017 as the base year.

Geographically, the global antifungal agents market has been segmented on the basis of four major regions, which include:

The Antifungal agents market in North America is expected to hold the largest share by 2026 owing to the huge investments made in drug productions along with the government initiatives related to fungal infections and their treatment. Endemic fungal infection follows distinct geographic distributions that are determined by the condition of the soil and climate, which would be optimal for the fungi’s growth. North America is home to 3 of the major endemic mycoses type: histoplasmosis, blastomycosis, and coccidioidomycosis. Although, the prevalence of these varies by region. On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the antifungal agents market. In India, the growing healthcare industry is boosting the antifungal agents market. Fungal infections are increasing year by year in China because of the application of immunosuppressant and wide-spectrum antibiotics. In Japan, increase in a number of fungal diseases is boosting the antifungal agent market, as antifungal agents are used to treat fungal infections.

The antifungal agents market is segmented based on drug types which are sub-divided into systemic azoles, topical azoles, systemic polyenes, topical polyenes, systemic echinocandins, systemic antimetabolics, other systemic, other topical, and other drugs types. It is also segmented on the basis of Therapeutic indications which are sub-divided into Aspergillosis, Dermatophytosis, Candidiasis, and others. On the basis of types, the market is categorized into Prescription and OTC. Echinocandins are characterized by their capability to prevent synthesis of a key component of the fungal cell wall. Azole antifungals are characterized by the capability to prevent ergosterol synthesis in fungal membranes. Aspergillosis refers to an infection that is caused by Aspergillus, i.e. a type of fungus. Dermatophytosis refers to a group of fungi that enter and grow in the dead keratin of hair, skin, and nails. Candidiasis refers to a fungal infection due to any type of yeast (Candida).

The major market players in the global antifungal agents market are:

  • Abbott Laboratories
  • Baxter
  • Bayer Healthcare
  • Johnson & Johnson
  • Pfizer

Company Profiles covers analysis of important players.

Abbott Laboratories was founded by Dr Wallace Calvin Abbott in 1888.  Abbott has experience and knowledge for more than 125 years. Abbott has products for all, from newborns to ageing adults, from diagnostics to pharmaceutical therapy and medical care. Another company, Pfizer, is an American global pharmaceutical company found in the year 1849. It is headquartered in New York City and comes in the list of the world’s largest pharmaceutical companies.

Key Findings of the Global Antifungal agents market:

  • Tropical drugs market is the emerging application
  • Aspergillosis therapeutic indication is leading the market
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
    • ESTIMATION METHODOLOGY
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • TROPICAL DRUGS MARKET IS THE EMERGING APPLICATION
      • ASPERGILLOSIS THERAPEUTIC INDICATION IS LEADING THE MARKET
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • POOR HYGIENE HABITS
      • DEVELOPMENT OF DRUG RESISTANCE
      • HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
    • MARKET RESTRAINTS
      • GROWING AGING POPULATION IN SOME REGIONS
      • ALTERNATE TREATMENT OPTIONS
      • REGULATORY ATMOSPHERE
    • MARKET OPPORTUNITIES
      • EMERGING PIPELINE OF NEW AND INNOVATIVE ANTIFUNGAL DRUGS
      • HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
      • INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
    • MARKET CHALLENGES
      • GROWTH AND DEVELOPMENT OF THE GENERIC ANTIFUNGAL DRUGS MARKET
      • SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
      • RESISTANCE TO DRUGS
      • RAPIDLY CHANGING TECHNOLOGY
  1. MARKET SEGMENTATION
    • MARKET BY DRUG TYPES 2018-2026
      • SYSTEMIC AZOLES
      • TOPICAL AZOLES
      • SYSTEMIC POLYENES
      • TOPICAL POLYENES
      • SYSTEMIC ECHINOCANDINS
      • SYSTEMIC ANTIMETABOLICS
      • OTHER SYSTEMIC
      • OTHER TOPICAL
      • OTHER DRUGS TYPES
    • MARKET BY THERAPEUTIC INDICATIONS 2018-2026
      • ASPERGILLOSIS MARKET
      • DERMATOPHYTOSIS MARKET
      • CANDIDIASIS MARKET
      • OTHER THERAPEUTIC INDICATION MARKET
    • MARKET BY APPLICATIONS 2018-2026
      • TOPICAL ANTIFUNGAL AGENTS MARKET
      • ORAL DRUGS MARKET
    • MARKET BY TYPES 2018-2026
      • PRESCRIPTION
      • OVER THE COUNTER (OTC)
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCE MODEL
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
      • BARGAINING POWER OF BUYER
      • BARGAINING POWER OF SUPPLIER
      • INTENSITY OF COMPETITIVE RIVALRY
    • KEY BUYING CRITERIA
    • VALUE CHAIN ANALYSIS
      • MANUFACTURERS
      • DISTRIBUTORS
      • RETAILERS
      • END-USERS
    • STRATEGIC RECOMMENDATION
    • STRATEGIC CONCLUSIONS
    • REGULATORY FRAMEWORK
      • REGULATION IN NORTH AMERICA
      • REGULATION IN EUROPE
      • REGULATION IN ASIA PACIFIC
      • REGULATION IN LATIN AMERICA
      • REGULATION IN MIDDLE EAST AND AFRICA
    • OPPORTUNITY MATRIX
  2. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES (U.S.)
      • CANADA
    • EUROPE
      • UNITED KINGDOM (UK)
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • BENELUX
      • SCANDINAVIA
      • AUSTRIA
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • SOUTH KOREA
      • TAIWAN
      • REST OF APAC
    • REST OF WORLD
      • LATIN AMERICA
        • BRAZIL
        • MEXICO
        • ARGENTINA
        • CHILE
        • REST OF LATIN AMERICA
      • MIDDLE EAST AND AFRICA (MEA)
  1. COMPANY PROFILES
    • COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
    • ABBOTT LABORATORIES.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ARBOR PHARMACEUTICALS, INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BAXTER
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ASTELLAS PHARMA INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BAYER HEALTHCARE
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • TEVA PHARMACEUTICALS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • GILEAD
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • GLAXOSMITHKLINE
      • COMPANY OVERVIEW
      • PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • JOHNSON & JOHNSON
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • KRAMER LABORATORIES
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • MERCK & CO.
      • COMPANY OVERVIEW
      • PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • NOVARTIS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • PFIZER
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SANOFI-AVENTIS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • VERTEX PHARMACEUTICALS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE

 

TABLE LIST

TABLE  1      GLOBAL ANTIFUNGAL AGENTS MARKET BY GEOGRAPHY 2018-2026 ($MILLION)

TABLE  2      SKIN LESIONS OCCURRING DUE TO ANTIFUNGAL INFECTION

TABLE  3      INDIAN GOVERNMENT INITIATIVES IN HEALTHCARE SECTOR

TABLE  4      GLOBAL ANTIFUNGAL AGENTS MARKET BY DRUG TYPES MARKET 2018-2026 ($ MILLION)

TABLE  5      DRUG USES OF TRIAZOLES

TABLE  6      GLOBAL ANTIFUNGAL AGENTS MARKET IN SYSTEMIC  AZOLES BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  7      GLOBAL ANTIFUNGAL AGENTS MARKET IN TOPICAL AZOLES BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  8      GLOBAL ANTIFUNGAL AGENTS MARKET IN SYSTEMIC POLYENES BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  9      GLOBAL ANTIFUNGAL AGENTS MARKET IN TOPICAL POLYENES BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  10    INDICATION AND DOSES OF ECHINOCANDIN BY US APPROVED DRUG USAGE

TABLE  11    GLOBAL ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ECHINOCANDINS BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  12    GLOBAL ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ANTIMETABOLICS BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  13    GLOBAL ANTIFUNGAL AGENTS MARKET IN OTHER SYSTEMIC BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  14    GLOBAL ANTIFUNGAL AGENTS MARKET IN OTHER TOPICAL BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  15    GLOBAL ANTIFUNGAL AGENTS MARKET IN OTHER DRUGS TYPES MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  16    GLOBAL ANTIFUNGAL AGENTS MARKET BY THERAPEUTIC INDICATIONS MARKET 2018-2026 ($ MILLION)

TABLE  17    GLOBAL ANTIFUNGAL AGENTS MARKET IN ASPERGILLOSIS BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  18    SYMPTOMS IN THE AFFECTED AREA CAUSED BY DERMATOPHYTES

TABLE  19    GLOBAL ANTIFUNGAL AGENTS MARKET IN DERMATOPHYTOSIS MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  20    SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS

TABLE  21    GLOBAL ANTIFUNGAL AGENTS MARKET IN CANDIDIASIS BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  22    GLOBAL ANTIFUNGAL AGENTS MARKET IN OTHER THERAPEUTIC INDICATION BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  23    GLOBAL ANTIFUNGAL AGENTS MARKET BY APPLICATIONS MARKET 2018-2026 ($ MILLION)

TABLE  24    PROS AND CONS OF TOPICAL MEDICATIONS

TABLE  25    ANTIFUNGAL POWDERS AND IT’S EFFECT

TABLE  26    ANTIFUNGAL OINTMENT AND IT’S EFFECT

TABLE  27    ANTIFUNGAL PASTES AND IT’S EFFECT

TABLE  28    GLOBAL ANTIFUNGAL AGENTS MARKET IN TOPICAL ANTIFUNGAL AGENTS BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  29    COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS

TABLE  30    GLOBAL ANTIFUNGAL AGENTS MARKET IN ORAL DRUGS BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  31    GLOBAL ANTIFUNGAL AGENTS MARKET BY TYPES 2018-2026 ($ MILLION)

TABLE  32    GLOBAL ANTIFUNGAL AGENTS MARKET IN PRESCRIPTION BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  33    GLOBAL ANTIFUNGAL AGENTS MARKET IN OTC BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  34    GLOBAL ANTI-FUNGAL AGENT MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  35    NORTH AMERICA ANTI-FUNGAL MARKET BY COUNTRIES 2018-2026 ($ MILLION)

TABLE  36    EUROPE ANTIFUNGAL AGENTS MARKET BY COUNTRIES 2018-2026( $ MILLION)

TABLE  37    TOTAL BURDEN OF FUNGAL INFECTIONS IN SPAIN 2016

TABLE  38    ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY COUNTRIES 2018-2026($ MILLION)

TABLE  39    INDIA’S HEALTHCARE SECTOR INVESTMENT

TABLE  40    COMPANIES IN CHINA PRODUCING ANTIFUNGAL DRUGS

TABLE  41    REST OF WORLD  ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

TABLE  42    LATIN AMERICA ANTIFUNGAL AGENTS MARKET  BY COUNTRIES 2018-2026($ MILLION)

 

FIGURES LIST

FIGURE  1    GLOBAL ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)

FIGURE  2    INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)

FIGURE  3    TOPICAL ANTIFUNGAL AGENTS TYPES

FIGURE  4    PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET

FIGURE  5    VALUE CHAIN OF ANTIDEPRESSANT DRUGS

FIGURE  6    THE UNITED STATES ANTI-FUNGAL AGENTS MARKET 2018-2026 ($ MILLION)

FIGURE  7    CANADA ANTIFUNGAL AGENT MARKET 2018-2026 ($ MILLION)

FIGURE  8    FINAL CONSUMPTION OF MEDICAL GOODS AND SERVICES BY HOUSEHOLD

FIGURE  9    THE UNITED KINGDOM ANTIFUNGAL AGENTS MARKET 2018-2026($MILLION)

FIGURE  10  INVESTMENT MADE BY DIFFERENT AGENTS IN FRANCE 2017(%)

FIGURE  11  FRANCE ANTI-FUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  12  GERMANY ANTI-FUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  13  SPAIN ANTI-FUNGAL MARKET 2018-2026($ MILLION)

FIGURE  14  ITALY ANTI-FUNGAL MARKET 2018-2026($ MILLION)

FIGURE  15  BENELUX ANTI-FUNGAL MARKET 2018-2026($ MILLION)

FIGURE  16  SCANDINAVIA  ANTI-FUNGAL MARKET 2018-2026($ MILLION)

FIGURE  17  AUSTRIA  ANTI-FUNGAL MARKET 2018-2026($ MILLION)

FIGURE  18  REST OF EUROPE ANTI-FUNGAL MARKET 2018-2026($ MILLION)

FIGURE  19  INDIA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  20  CHINA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  21  JAPAN ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  22  SOUTH KOREA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  23  TAIWAN ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  24  REST OF APAC ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  25  LATIN AMERICA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  26  BRAZIL  ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  27  MEXICO  ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  28  ARGENTINA  ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  29  CHILI  ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  30  REST OF LATIN AMERICA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  31  VARIOUS SECTORS INVESTMENTS IN THE MEA REGION

FIGURE  32  MIDDLE EAST AND AFRICA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE  33  ANTI-FUNGAL AGENT COMPANY MARKET SHARE ANALYSIS  2017 (%)

  1. MARKET SEGMENTATION
    • MARKET BY DRUG TYPES 2018-2026
      • SYSTEMIC AZOLES
      • TOPICAL AZOLES
      • SYSTEMIC POLYENES
      • TOPICAL POLYENES
      • SYSTEMIC ECHINOCANDINS
      • SYSTEMIC ANTIMETABOLICS
      • OTHER SYSTEMIC
      • OTHER TOPICAL
      • OTHER DRUGS TYPES
    • MARKET BY THERAPEUTIC INDICATIONS 2018-2026
      • ASPERGILLOSIS MARKET
      • DERMATOPHYTOSIS MARKET
      • CANDIDIASIS MARKET
      • OTHER THERAPEUTIC INDICATION MARKET
    • MARKET BY APPLICATIONS 2018-2026
      • TOPICAL ANTIFUNGAL AGENTS MARKET
      • ORAL DRUGS MARKET
    • MARKET BY TYPES 2018-2026
      • PRESCRIPTION
      • OVER THE COUNTER (OTC)
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES (U.S.)
      • CANADA
    • EUROPE
      • UNITED KINGDOM (UK)
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • BENELUX
      • SCANDINAVIA
      • AUSTRIA
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • SOUTH KOREA
      • TAIWAN
      • REST OF APAC
    • REST OF WORLD
      • LATIN AMERICA
        • BRAZIL
        • MEXICO
        • ARGENTINA
        • CHILE
        • REST OF LATIN AMERICA
      • MIDDLE EAST AND AFRICA (MEA)

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    Choose License Type

    Buy Now